Susquehanna International Group
GERM

Susquehanna International Group’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Susquehanna International Group’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-46,695
Closed -$850K – 13450
2024
Q2 		$850K Buy
46,695
+5,382
+13% +$98.5K ﹤0.01% 6971
2024
Q1 		$761K Buy
41,313
+7,173
+21% +$133K ﹤0.01% 7521
2023
Q4 		$668K Buy
34,140
+12,994
+61% +$227K ﹤0.01% 7960
2023
Q3 		$378K Buy
21,146
+9,209
+77% +$180K ﹤0.01% 8856
2023
Q2 		$246K Buy
+11,937
New +$250K ﹤0.01% 9844
2023
Q1 		– Sell
-49,144
Closed -$1.1M – 13827
2022
Q4 		$1.1M Buy
49,144
+9,966
+25% +$225K ﹤0.01% 5967
2022
Q3 		$812K Buy
39,178
+5,303
+16% +$129K ﹤0.01% 7177
2022
Q2 		$788K Buy
33,875
+20,700
+157% +$493K ﹤0.01% 7114
2022
Q1 		$361K Buy
+13,175
New +$371K ﹤0.01% 9809

Other funds holding GERM

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's GERM Position: Q3 2024 in Review

Susquehanna International Group sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q3 2024, closing a stake of 46,695 shares — an estimated $850K sold.

Susquehanna International Group first reported a position in GERM in Q1 2022 and held it in 9 quarters. The position peaked at $1.1M in Q4 2022. 1 fund tracked by Wall St. Rank holds GERM as of Q3 2024.

  • Susquehanna International Group reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 46,695 Amplify Treatments, Testing and Advancements ETF shares in Q3 2024, an estimated $850K.
  • Susquehanna International Group first reported a position in Amplify Treatments, Testing and Advancements ETF in Q1 2022 and held it in 9 quarters.
  • Susquehanna International Group's Amplify Treatments, Testing and Advancements ETF position peaked at $1.1M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.